At NINGBO INNO PHARMCHEM CO.,LTD., we are committed to providing high-quality chemicals that underpin scientific advancements. Cilengitide, a notable synthetic peptide, exemplifies this commitment with its sophisticated mechanism of action as a selective integrin antagonist.

Cilengitide is designed to target specific integrin receptors, namely αvβ3 and αvβ5. Integrins are heterodimeric transmembrane glycoproteins that mediate cell adhesion and signaling. They are implicated in a vast array of biological processes, including cell growth, migration, differentiation, and survival. In the context of cancer, the dysregulation of integrin function, particularly the overexpression of αvβ3 and αvβ5, is a hallmark of many malignancies. These integrins are crucial for tumor angiogenesis, invasion, and metastasis. Therefore, developing selective integrin antagonists like Cilengitide is a key strategy in modern oncology.

The scientific basis for Cilengitide's efficacy lies in its structural mimicry of the Arg-Gly-Asp (RGD) motif, a common recognition sequence found in extracellular matrix proteins that bind to integrins. By presenting this RGD sequence in a constrained cyclic peptide format, Cilengitide achieves high affinity and selectivity for αvβ3 and αvβ5 integrins. This selectivity is crucial for minimizing off-target effects and maximizing therapeutic benefit. Researchers looking for precise tools to study integrin function often search for 'selective RGD peptide' or 'cilengitide mechanism of action'.

In vitro and in vivo studies have demonstrated that Cilengitide effectively blocks integrin-mediated processes, including endothelial cell adhesion to vitronectin and fibronectin, endothelial cell proliferation and migration, and the formation of new blood vessels. It has also been shown to induce apoptosis in endothelial cells and inhibit tumor cell adhesion and invasion. The ability to buy Cilengitide from a reputable supplier like NINGBO INNO PHARMCHEM CO.,LTD. ensures that researchers have access to a reliable tool for exploring these fundamental cellular processes.

The development of Cilengitide underscores the power of peptide-based therapeutics and the importance of targeting specific molecular pathways in disease. Its potential applications extend beyond glioblastoma to other cancers where αvβ3 and αvβ5 integrins play a significant role. Continued research into Cilengitide will undoubtedly shed more light on the intricate interplay between integrins and disease progression.

In summary, Cilengitide's status as a selective integrin antagonist makes it a valuable compound in biomedical research. NINGBO INNO PHARMCHEM CO.,LTD. is proud to support the scientific community by providing high-quality Cilengitide for studies aimed at understanding and combating diseases driven by aberrant integrin signaling.